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Summary
Obesity is caused by chronic positive energy balance because of higher energy
intake relative to energy expenditure. Thermogenesis, the capacity of an organism
to produce heat, is an important component of energy expenditure. Thus targeting
the molecular mechanisms controlling thermogenesis could be an effective strat-
egy for the prevention or treatment of obesity. Thermogenesis is modulated by
three major factors: environmental temperature, nutrient quantity and quality,
and by systemic inﬂammation. Obesity is now recognized to be a state of chronic
low-grade systemic inﬂammation, which has been proposed to play a major role
in the pathogenesis of obesity and obesity-associated diseases. This review dis-
cussed the molecular pathways that are recruited during metabolic inﬂammation
and that are also implicated in the control of thermogenesis and energy balance.
It emerges that the complex signalling network recruited during metabolic inﬂam-
mation exerts a balanced action on the modulation of thermogenesis and energy
balance, with some pathways promoting weight gain whereas other pathways
have opposite actions. It is thus concluded that immunomodulation of metabolic
inﬂammation, rather than an anti-inﬂammatory intervention aiming at its sup-
pression, may be a more promising strategy to increase thermogenesis for the
treatment or prevention of obesity and its associated diseases.
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Innate immunity and thermogenesis:
basic concepts
Obesity is caused by chronic positive energy balance result-
ing from a higher energy intake relative to energy expendi-
ture. Understanding the molecular mechanisms controlling
energy balance is thereby fundamental to the development
of novel interventions for the treatment or prevention of
obesity. Homeotherm organisms, including humans and
laboratory rodents, dissipate a large proportion of their
ingested food energy to the environment in the form of heat
(1). This capacity of living organisms to generate heat is
generally referred to as thermogenesis (2). Thermogenesis
is variable among different individuals and is modulated by
environmental factors (2). There are essentially three major
environmental factors that potently inﬂuence thermogen-
esis: environmental temperature (e.g. cold-induced thermo-
genesis), food quantity and quality (e.g. diet-induced
thermogenesis), and systemic inﬂammation in response to
infection or tissue damage (e.g. fever) (2,3). Thermogenesis
is chieﬂy controlled by the sympathetic nervous system
(SNS) and depends on b-adrenergic receptors (4,5), which
mediate the effects of norepinephrine and other catecho-
lamines (3,6,7). Increased norepinephrine turnover was
reported in the heart, white adipose tissue (WAT), and
brown adipose tissue (BAT) in response to thermogenic
stimuli like diet and cold (8,9). Binding of catecholamines
to brown adipocyte b-adrenergic receptors activates a ther-
mogenic programme including induction of lipolysis and
uncoupling protein (UCP)-1 activity and gene expression
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(6,7). b-adrenergic signalling in white adipocytes and car-
diomyocytes is likely to play an important role in sustaining
thermogenesis by providing fatty acid substrates from
lipolysis that are transported to the BAT via an increased
blood ﬂow (Fig. 1).
The adipocyte-derived hormone leptin plays a major
role in sustaining thermogenesis (Fig. 1). Indeed, mutant
mice with defective leptin signalling display dramatically
decreased sympathetic tone in BAT (10,11), in addition to
showing impaired thermogenic response to cafeteria diet
(12) and cold intolerance (13).
The SNS and more generally the nervous system are
tightly interconnected with the immune system. These
systems inﬂuence each other in a bidirectional manner and
share similar molecular mechanisms (14). Indeed, on the
one hand, the SNS is known to play a powerful action on
white blood cells to control immunity (15), and it has
also been shown that leukocytes themselves produce cat-
echolamines to modulate the immune reaction (16,17).
Furthermore, macrophage-mediated immunity and reactive
oxygen species production have been shown to be modu-
lated by the UCP-2, a protein with high sequence similarity
to UCP-1 (18). On the other hand, the innate-immune
system exerts a powerful control on the SNS and thermo-
genesis. Fever can be seen as a paradigm of such neuro-
immune interaction where pathogens activate leukocytes
and other cells leading to increased levels of pro-
inﬂammatory mediators whose action on the central
nervous system results in increased core body temperature
(Fig. 1). The precise cellular and molecular mechanism con-
trolling fever is still not completely understood and different
mechanisms are recruited in different models. However,
three central molecular mediators of the febrile response to
exogenous pyrogens such as bacterial endotoxin have been
identiﬁed: the toll-like receptor 4 (TLR-4), the pyrogenic
cytokines and the pyrogenic prostaglandins (19–22).
Pathogen-associatedmolecular patterns (PAMPs) are sensed
by speciﬁc receptors such as TLR-4, the sensor of bacterial
lipopolysaccharides (LPS). Once activated, TLR-4 receptors
lead to the activation of different kinases including mitogen-
activated protein kinases (MAPK) and the inhibitor of
kappa-B kinase (IKK) complex, which are responsible,
respectively, for the activation of the transcription factors
activator protein 1 (AP-1) and nuclear factor kappa-B (NF-
kB), leading to increased expression of inﬂammatorymedia-
tors (23). Pyrogenic cytokines, most notably the interleukins
(IL) IL-1 and IL-6, are the primary endogenous pyrogens
and are produced in response to either PAMPs or damage-
associated molecular patterns (DAMPs) (19–22). Both
endogenous pyrogenic cytokines and exogenous pyrogens
Figure 1 Essential elements in the regulation of thermogenesis. Thermogenesis is modulated essentially by three factors: (i) environmental
temperature; (ii) food quality and quantity; and (iii) systemic inﬂammation. It is well established that the induction of thermogenesis by cold and diet
depends on the sympathetic nervous system (SNS). Increased catecholamine turnover was observed in brown adipose tissue and in the heart in
response to cold and cafeteria diet, and in retroperitoneal white adipose tissue in response to dietary glucose or fructose. Some studies indicate that
the immune system also modulate thermogenesis via the sympathetic nervous system. Systemic inﬂammation can lead to either fever or hypothermia,
depending on the experimental conditions. The thermogenic outcome of systemic inﬂammation depends on the balanced action of pyrogenic cytokines
(e.g. interleukin [IL]-1b, and IL-6) and antipyrogenic/anti-inﬂammatory cytokines (e.g. IL-1Ra and IL-10). Leptin signalling is known to be required for an
efficient induction of thermogenesis by cold and food. cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase 2; LPS, lipopolysaccharides;
PAMPs, pathogen-associated molecular patterns; PGE2, prostaglandin E2; PKA, protein kinase A; UCP-1, uncoupling protein.
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(e.g. LPS) induce the expression of the gene encoding for the
cyclooxygenase 2 (COX-2), the enzyme responsible for the
production of pyrogenic and inﬂammatory prostaglandins
such as PGE2 (prostaglandin E2) (19–22). Overall, LPS and
pyrogenic cytokines can induce a complex physiological
response leading to higher core body temperature by a
mechanism that depends on COX-2 activity (24,25) and
that involves increased thermogenesis partly because of the
activation of SNS (26,27) (Fig. 1).
It is important to consider that, in addition to fever,
systemic inﬂammation can also cause hypothermia depend-
ing on the experimental conditions (28,29). Indeed, fever
and hypothermia are both clinical signs of sepsis. It is well
established in mouse models that the effects of LPS on core
temperature depends on dose, route of administration and
environmental temperature (28,29). Indeed, intraperitoneal
injection of a low dose of LPS (50 mg kg-1) is known to
cause fever without hypothermia, whereas a higher dose
of LPS (2.5 mg kg-1) causes a ‘multiphase’ response with
hypothermia preceding fever, and ﬁnally, a lethal dose of
LPS (10 mg kg-1) was reported to induce sustained hypo-
thermia (28). Furthermore, a hypothermic phase preceding
fever was also observed in the caecal–ligation puncture
model, which reproduces sepsis (28). Our current under-
standing of the mechanisms of hypothermia in systemic
inﬂammation is poor compared with our understanding
of fever. Systemic inﬂammation-induced hypothermia may
be at least in part explained by increased heat loss,
although the precise mechanism remains to be established
and suppression of thermogenesis may also play an impor-
tant role. Overall, it is evident that during systemic inﬂam-
mation, several cytokines and other signalling molecules
are released: some cytokines display clear pyretic effects
(e.g. IL-1, and IL-6) whereas others are antipyretic (e.g.
IL-1Ra and IL-10) (30) (Fig. 1). Thus, the ﬁnal effect of
systemic inﬂammation on body core temperature and ther-
mogenesis is likely the outcome of the integrated action of
the speciﬁcally recruited signalling network. Interestingly,
the pro-inﬂammatory cytokine tumour necrosis factor
(TNF) a was reported to display both pyretic and antipy-
retic activity depending on the speciﬁc model in which its
action is tested. TNFa can be considered a pyrogen as
intravenous injection of TNFa causes fever in different
species by a mechanism involving SNS-dependent induc-
tion of thermogenesis (31–33). However, the pyrogenic
action of TNFa depends on the speciﬁc experimental
model as TNFa was also reported to act as antipyretic and
promote LPS-induced hypothermia (34–36). Interestingly,
one study showed an association between TNFa-induced
hypothermia and decreased sympathetic outﬂow to BAT
(37), suggesting that at least in some conditions, TNFa
signalling may decrease thermogenesis. Thus, considering
the powerful actions of different cytokines in the regulation
of SNS-mediated thermogenesis, it is possible that signal-
ling pathways implicated in innate immunity may also be
involved in the control of energy balance and body weight
homeostasis.
Obesity is a state of low-grade chronic
systemic inﬂammation
Obesity is an inﬂammatory condition characterized by
elevated levels of pro-inﬂammatory cytokines, accumula-
tion of leukocytes within adipose tissue and other organs,
activation of macrophages in liver and fat, and activation
of pro-inﬂammatory signalling pathways in multiple
organs (38–43). Inﬂammation can be triggered by patho-
gens or by tissue damage, and although the precise mecha-
nism causing inﬂammation during obesity is still under
investigation, two main mechanisms have been proposed:
one focused on metabolic endotoxemia and the other one
on metabolic stress. Concerning the former hypothesis, it
was reported that the gut microbial population is altered in
obese mice independently of the diet (44), and that feeding
mice on a high-fat diet (HFD) causes a state of chronic
low-grade endotoxemia, which was proposed to be an ini-
tiating factor of obesity-induced inﬂammation (45). The
second mechanism proposed to underlie metabolic inﬂam-
mation focuses on metabolic stress caused by excess nutri-
ents. During positive energy balance, excess calories are
safely stored in adipocytes as triglycerides. However, when
the adipose tissue expandability limit is achieved, toxic
lipids accumulate in non-adipose tissues causing metabolic
stress and activating pro-inﬂammatory signalling cascades
(38–42,46–48). At the same time, the hypertrophic adi-
pocytes die by necrosis causing leukocyte inﬁltration into
WAT with activated macrophages accumulating around the
lipid vacuole from dead adipocytes to form typical crown-
like structures (49). In support for the idea of a crucial role
for adipose tissue expandability in metabolic inﬂammation
is the demonstration that a similar inﬂammation to the one
observed in obesity models is also observed in lipodys-
trophic mice, where adipocyte hypertrophy and fat storage
saturation are achieved in non-obese mice on a low-fat
diet (49,50).
Overall, obesity is an inﬂammatory state where signals
reported to exert powerful effects on thermogenesis are
chronically recruited. As described earlier, acute systemic
immune reactions can have powerful effects in either
increasing or decreasing body core temperature depending
on the speciﬁc model. Such powerful and opposing effects of
the immune system on core body temperaturemay in part be
explained by the speciﬁc signalling network recruited in the
speciﬁc context. It is therefore important to note that meta-
bolic inﬂammation is characterized by a distinct cytokine-
signalling network. The obese adipose tissue is characterized
by the accumulation of pro-inﬂammatory leukocytes and
polarization of the local macrophage population from M2
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(typically anti-inﬂammatory) towards an M1 phenotype
(typically pro-inﬂammatory) (51,52). This is paralleled by a
low-grade but chronic elevation of the production of pro-
inﬂammatory pyrogenic cytokines, and decreased expres-
sion of the anti-inﬂammatory cytokine IL-10 (51,52).
Despite the clear pro-inﬂammatory ‘cytokine signature’
associated with obesity, it is important to note that among
the cytokines displaying the largest induction of gene expres-
sion in the obese adipose tissue one can ﬁnd the IL-1 receptor
antagonist (IL-1Ra), a most powerful anti-inﬂammatory
and antipyretic cytokine whose function is to antagonize
IL-1 signalling (30,53–55) (Fig. 2).
Exogenous pyrogens and pathogen-associated
molecular patterns receptors in obesity-
induced inﬂammation and thermogenesis
PAMPs from gram-negative bacteria are most potent exog-
enous pyrogens, which paradoxically can also cause hypo-
thermia depending on the experimental conditions. Gut
microbiota has been identiﬁed as an environmental factor
implicated in energy balance (56). The gut microbial popu-
lation is altered during obesity (44), and it has been shown
that HFD increases the circulating levels of LPS (45). In a
study investigating the effects of metabolic endotoxemia on
obesity, LPS levels were chronically elevated to the concen-
tration observed in HFD-fed mice for 4 weeks by continu-
ous LPS infusion using an osmotic pump (45). Strikingly,
LPS-infused mice kept on low-fat diet displayed higher
weight gain than control saline-infused mice on low-fat
diet, with the greater weight gain being similar to mice kept
on HFD. However, whereas the increased weight gain on
HFD-fed mice compared with low-fat diet-fed mice was
largely due to increased energy intake, in LPS-infused mice
energy intake was signiﬁcantly lower than HFD-fed mice
and similar to the one observed in low-fat diet-fed mice.
This observation suggests that chronic low-grade endotox-
emia may promote feed efﬁciency by reducing apparent
energy expenditure.
TLR-4 was identiﬁed as a major sensor for bacterial
LPS, and it was proposed that TLR-4 might be a sensor
for saturated free fatty acids (57). Nonetheless, the role of
TLR-4 in diet-induced obesity is less obvious as different
studies investigating TLR-4 loss of function in mice models
of diet-induced obesity have reported different results,
ranging from increased predisposition to obesity to a dra-
matic protection from diet-induced obesity compared with
wild-type (WT) control mice (57–59). Whereas such dis-
crepancies suggest that the impact of TLR-4 signalling on
energy balance may depend on the speciﬁc experimental
conditions, it should be noted that when loss of functional
TLR-4 was linked to increased weight gain, this was largely
due to increased food intake (57), whereas when resistance
to diet-induced obesity was observed, this was explained by
increased thermogenesis (58). Thus, it cannot be excluded
that TLR-4 signalling might have opposing effects on food
intake and thermogenesis in models of diet-induced obesity
and might therefore either promote or antagonize positive
energy balance depending on the speciﬁc experimental con-
dition. Still, the precise role of TLR-4 on thermogenesis and
energy balance in body weight homeostasis and obesity
remains to be established.
The nucleotide-binding oligomerization domain-like
receptors (NLR) are a family of intracellular PAMPs and
DAMPs receptors implicated in pathogen and damage
sensing (60). A study reported that mice lacking two NLR
family members NOD1 and NOD2 display reduced
adiposity when placed on HFD compared with WT mice
(61). However, this leaner phenotype could be partially
explained by increased spontaneous physical activity and
decreased food intake. Thus, at this stage, it is not clear
whether NOD1 and NOD2 may also play a role in the
control of thermogenesis. Another NLR family member
that was recently implicated in metabolic inﬂammation
and energy balance is the NOD-like receptor NLRP-3
Figure 2 Possible actions of adipokines in the control of thermogenesis
during obesity. The obese adipose tissue is characterized by leucocyte
inﬁltration, a chronic low-grade induction of pro-inﬂammatory cytokines
(e.g. tumour necrosis factor-a [TNFa], interleukin [IL]-6 and IL-1b), and
by increased levels of the anti-inﬂammatory cytokine IL-1Ra. The
classical pyrogenic cytokines IL-6 and IL-1b, as well as IL-18 were
proposed to antagonize positive energy balance and to sustain
thermogenesis. By contrast, evidence suggests that IL-1Ra may
promote positive energy balance by suppressing sympathetic tone.
Some evidence suggests that TNFa may also promote positive energy
balance and negatively regulate thermogenesis. As indicated here,
these cytokines may control thermogenesis via the sympathetic nervous
system (SNS). However, possible peripheral actions should also be
considered. Intact leptin signalling is known to be a basic requirement
for efficient thermogenesis in response to cold and food. Thus
insufficient leptin signalling (e.g. leptin resistance) may lead to
defective thermogenesis promoting positive energy balance and
obesity.
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(NOD-like receptor family, pyrin domain containing
protein). NLRP-3 is an intracellular receptor that forms a
large complex with other proteins called the inﬂammasome,
which is implicated in sensing different PAMPs and DAMPs
(62). Activation of NLRP-3 leads to the recruitment of the
caspase-1 protease via the adaptor protein ASC (apoptosis-
associated speck-like protein containing a carboxy-terminal
CARD), leading to proteolytic cleavage of IL-1b and IL-18
precursors to generate their mature forms, which are then
secreted. Mutations of NLRP-3 in humans, also known as
cryopyrin, were found to cause familial cold autoinﬂamma-
tory syndrome, a rare genetic disease characterized by epi-
sodes of systemic inﬂammation and fever triggered or
exacerbated by acute cold exposure (63,64). Thus, such
genetic condition strongly suggests that on top of the func-
tion of pathogen and damage sensor, NLRP-3might also act
as a ‘cold sensor’. NLRP3was proposed to play amajor role
in linking obesity-induced lipotoxicity to metabolic inﬂam-
mation and insulin resistance. Indeed, mice lacking NLRP-3
display decreased inﬂammasome activation and improved
insulin sensitivity in models of diet-induced obesity (65).
However, it is important to notice that in this study, mice
lackingNLRP-3 kept onHFD showed decreased epididymal
fat pad weight and dramatically decreased adipocyte size
and lipid accumulation in the liver compared with WT
control mice. These data suggest that at least part of the
beneﬁcial effects of NLRP-3 inactivation on metabolic
inﬂammation and insulin resistance could be the indirect
consequence of decreased adiposity and ectopic lipid, sug-
gesting a role for NLRP-3 and the inﬂammasome in energy
balance. Consistent with this interpretation, another study
showed that mice lacking either NLRP-3, the adapter ASC
or caspase-1 inﬂammasome proteins display decreased
weight gain compared with WT control mice kept on HFD
(66). Mice lacking one of the essential inﬂammasome com-
ponents (NLRP-3, ASC or caspase-1) and WT control mice
displayed similar caloric intake suggesting that differences in
weight gain are likely due to decreased feeding efﬁciency and
hence to increased apparent energy expenditure of mutant
mice (66). Consistently, compared with WT controls, mice
lacking caspase-1 displayed increased energy expenditure on
a HFD, as measured by indirect calorimetry. These latter
results are in sharp contrast with a more recent study
showing a protective action of the inﬂammasome in the
progression of diet-induced obesity, glucose intolerance and
non-alcoholic fatty liver disease, bymaintaining a ‘healthier’
gut microbiota (67). Collectively, these studies suggest that
the inﬂammasome complex plays an important role in the
control of thermogenesis and energy balance in mice models
of diet-induced obesity. Overall, the interpretation of these
studies is complex, and for the future, it will be important to
discriminate between possible role of the inﬂammasome in
the ecology of gut microbiota and the direct effects on
thermogenesis, energy balance and glucose homeostasis.
Obesity-induced inﬂammation and
thermogenesis: possible roles for
pyrogenic cytokines
Interleukin-6 and interleukin-1
The major pyrogenic cytokines IL-6 and IL-1 are elevated in
adipose tissue and blood during obesity and were proposed
to play an important role in obesity-induced glucose intol-
erance. However, as IL-6 and IL-1 activate thermogenesis
during fever (19,20), it is possible that IL-6 and IL-1 could
play a protective role in models of diet-induced obesity
by promoting thermogenesis, thus antagonizing positive
energy balance and the development of obesity. Consistent
with this view is the report that mice lacking IL-6 sponta-
neously develop mature-onset obesity on a standard low-fat
diet (68), a phenotype that was partially explained by the
central effects of IL-6 on thermogenesis (68,69). However,
in another study, age-related obesity was not observed in
mice lacking IL-6 (70), thereby suggesting that the presence
of IL-6 is not an essential requirement for body weight
homeostasis. Yet, a third study reported that mice lacking
IL-6 and IL-1 display increased weight gain, although this
could be largely explained by increased food intake (71).
IL-1 signalling was proposed to play an important role in
leptin-mediated control of energy balance and thermogen-
esis (72). Since then, several studies have supported the
concept of a role for IL-1 as a thermogenic signal implicated
in the control of body weight. Indeed it has been shown that
mice that do not express IL-1Ra, a most potent antagonist
of IL-1 signalling, display decreased weight gain and
increased energy expenditure (73). This observation was
conﬁrmed by another laboratory, which also correlated the
decreased weight gain and increased energy expenditure
observed in mice lacking IL1-Ra with increased sympathetic
tone (74). Consistently, it was reported that mice lacking
IL-1 receptor develop mature-onset obesity (75), a pheno-
type that was partially explained by decreased leptin sensi-
tivity. It is important to note that IL-1Ra gene expression is
markedly induced in obese WAT (53,54). IL-1b expression
is also induced in obese WAT, but to a lower extent than
IL1-Ra (53,54). Overall these data suggest that during
obesity, decreased IL-1 signalling because of increased
IL-1Ra levels may promote feed efﬁciency and positive
energy balance (Fig. 2).
Interleukin-18
The cytokine IL-18, which like IL-1b, is processed into its
active form by the inﬂammasome complex, has also been
implicated in the control of energy expenditure. Indeed,
mice lacking IL-18 display increased feed efﬁciency and
reduced oxygen consumption compared with WT control
mice (76,77). These studies on the role of IL-1 and
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IL-18 on energy balance are paradoxical with the one on
the inﬂammasome complex described earlier, where mice
lacking key inﬂammasome components are resistant to
diet-induced obesity because of increased energy expendi-
ture despite defective IL-1 and IL-18 processing (65,66).
Again, it was recently reported that the inﬂammasome is
implicated in the control of intestinal microbiota, and
that lack of inﬂammasome function leads to alteration
of the gut microbiota predisposing to obesity (67). Thus,
resolving these apparent paradoxes will be important
to better understand the complex action of the inﬂam-
masome, IL-1 and IL-18 in metabolic homeostasis and
thermogenesis.
Tumour necrosis factor-a
Another pro-inﬂammatory cytokine whose expression is
induced during obesity is TNFa. Blocking TNFa signalling
either using neutralizing antibodies or by genetic deletion of
the TNFa gene or both its receptors TNFR1 and TNFR2
genes was reported to improve glucose homeostasis in
rodent models of obesity without affecting body weight
(78,79). However, it was also reported that genetically
obese ob/ob mice, which also lack TNFR1 or both TNFR1
and TNFR2, display increased b3-adrenergic receptor and
UCP-1 mRNA levels in BAT, reduced brow adipose tissue
apoptosis and increased number of multilocular brown
adipocytes compared with ob/ob mice expressing TNFR1
(80). Furthermore, incubation of cultured brown adi-
pocytes with TNFa caused decreased b3-adrenergic recep-
tor mRNA levels and defective cAMP (cyclic adenosine
monophosphate) production in response to b3-adrenergic
receptor agonist (80). Collectively, these results suggest that
TNFa via TNFR1 decreases b3-adrenergic receptor signal-
ling in BAT and thus TNFR1 could be an important nega-
tive regulator of BAT activation. Most importantly, ob/ob
mice lacking TNFR1 and TNFR2 showed improved capac-
ity to maintain core body temperature when exposed to
cold (4°C) compared with ob/ob mice with intact TNFa
signalling, thus revealing an important role for TNFa sig-
nalling as negative modulator of cold-induced thermogen-
esis (80). Interestingly, in this study, body weight was
signiﬁcantly reduced in TNFR-deﬁcient female ob/ob mice
compared with ob/ob mice expressing the TNFa receptors,
suggesting that TNFa signalling may be implicated in body
weight regulation. Consistent with this view, another labo-
ratory reported that mice speciﬁcally lacking TNFR1 sig-
nalling, but expressing a functional TNFR2 were protected
from diet-induced obesity, a phenotype that was explained
by increased thermogenesis (81). Overall these studies on
TNFa signalling in cold-induced thermogenesis and energy
balance are consistent with the previously proposed role for
TNFa as antipyretic and negative modulator of the SNS-
BAT axis during fever (34–37) (Fig. 2). Whether TNFR2 is
also implicated in the control of thermogenesis and whether
there is a speciﬁc crosstalk between TNFR1 and TNFR2
signalling in thermogenesis remains to be established.
Ciliary neurotropic factor
The cytokine ciliary neurotrophic factor (CNTF), which so
far, was not directly implicated in metabolic inﬂammation,
emerged for its potential as antiobesogenic drug (82,83).
CNTF is a pleiotropic cytokine that was identiﬁed as
neuron-survival factor (84) and was later found to be an
endogenous pyrogen (85), although its physiological role in
systemic inﬂammation and fever remains to be established.
During a clinical trial for the treatment of amyotrophic
lateral sclerosis with recombinant CNTF it was observed
that obese patients receiving CNTF signiﬁcantly lost weight
compared with placebo-treated patients, suggesting an
important role for CNTF in energy balance (86,87). Mouse
studies show that the antiobesogenic action of CNTF is
largely leptin independent (88). Similarly to leptin, CNTF
acts on hypothalamic neurons to decrease food intake and
increase thermogenesis and UCP-1 gene expression in BAT
(88,89), and peripherally to promote AMPK (5’ adenosine
monophosphate-activated protein kinase)-dependent fatty
acid oxidation (90). Differently from leptin, CNTF was
also shown to induce COX-2 gene expression in brain
vascular tissue (91). Thus, it is possible that CNTF, like
other pyrogens, induces thermogenesis via COX–2-
dependent activation of the SNS. Indeed, the CNTF recep-
tor CNTFRa, similarly to IL-6 receptor, signals via gp130
protein and CNTF was also shown to bind to the IL-6
receptor (92–94); thus IL-6 and CNTF are recruiting dis-
tinct, but overlapping signalling networks.
A possible role for leukocytes in thermogenesis
and energy balance
Overall the studies above suggest that the speciﬁc cytokine
network recruited during obesity might have profound
effects on energy balance. The obese WAT is characterized
by leukocyte accumulation, polarization of resident mac-
rophages towards a so-called M1 ‘pro-inﬂammatory’ phe-
notype, and induction of pro-inﬂammatory cytokine gene
expression including TNFa, IL-1 and IL6. The speciﬁc
impact of M1-activated pro-inﬂammatory macrophages on
energy balance and thermogenesis during obesity remains
to be established. However, it was recently reported that
cold exposure induces alternative activation of macro-
phages towards an ‘M2 anti-inﬂammatory’ phenotype (95).
Most notably, the authors show that mice with defective
macrophage alternative M2 activation display cold intoler-
ance, which was explained by defective lipolysis in WAT,
depletion of BAT lipid storage, and decreased BAT activa-
tion. Thus the study mentioned earlier suggests an impor-
tant role for alternatively activated M2 macrophages in the

ht
tp
://
do
c.
re
ro
.c
h
promotion of lipolysis and thermogenesis. By contrast,
another study reported that during caloric restriction, a
condition characterized by increased lipolysis and sup-
pressed thermogenesis, macrophages accumulate to WAT
to decrease glycerol and FFA efﬂux from lipolysis (96).
Thus it will be important to test whether classically acti-
vated M1 ‘pro-inﬂammatory’ macrophages and alterna-
tively activated M2 ‘anti-inﬂammatory’ macrophages play
opposing roles in lipolysis and thermogenesis.
In addition to a possible role for macrophages in ther-
mogenesis, it was shown that genetic deﬁciency or pharma-
cological stabilization of mast cells leads to decreased
weight gain in a mouse model of diet-induced obesity (97).
Whereas this study suggests a role for mast cells in the
control of energy balance during obesity, it remains to be
established whether mast cells modulate thermogenesis and
feed efﬁciency rather than digestible energy intake.
Overall, the major pro-inﬂammatory cytokines induced
during obesity have somehow been implicated in the
control of thermogenesis and energy balance. A more
detailed understanding of the speciﬁc cytokine network
recruited during obesity and its action on thermogenesis
and energy balance may thus be fundamental for novel
strategies to treat or prevent obesity.
The cyclooxygenase-2 in thermogenesis and
energy balance
Pyrogenic cytokines and exogenous pyrogens such as
bacterial LPS are believed to activate the SNS and thermo-
genesis by a mechanism involving COX–2-mediated pro-
duction of pyrogenic prostaglandins. A possible role for
COX-2 in energy balance was suggested by a study
showing that mice that are heterozygous for a COX-2 null
mutation, with reduced COX-2 levels, display increased
weight-gain and adiposity compared with control mice
(98). Curiously, the same authors reported that mice
bearing the COX-2 null mutation on both alleles, which
did not express COX-2, showed similar body weight and
adiposity compared with WT control mice. Furthermore,
another study reported that whereas mice lacking COX-2
display similar body weight to WT control mice until the
age of 6 months, by the age of 9 months mice lacking
COX-2 gained much less weight that WT controls despite
similar food consumption (99). These studies suggest that
COX-2 may be implicated in the control of energy balance
by a dose- and age-dependent mechanism.
Recently, COX-2 was implicated in cold-induced ther-
mogenesis. Indeed two different laboratories reported that
cold exposure leads to increased COX-2 expression in
adipose tissue of mice, which correlate with the expression
of markers for BAT differentiation (100,101). This induc-
tion of COX-2 gene expression was recapitulated by
treatment of mice with a b3-adrenergic receptor agonist
suggesting that cold-induced COX-2 gene expression is
mediated by increased sympathetic activity. Mice lacking
COX-2 activity were less able to maintain core body tem-
perature in the cold and showed defective induction of
markers for BAT differentiation in inguinal WAT compared
with control mice expressing COX-2 (100,101). Impor-
tantly, mice treated with indomethacin, a non-selective
COX inhibitor displayed increased weight gain and adipos-
ity, despite the fact that energy intake was not increased
compared with control mice (100). Furthermore, it was
shown that mice overexpressing COX-2 in WAT gained
less weight than control mice kept on either low-fat or
HFD. Consistently, compared with WT control mice, the
transgenic mice overexpressing COX-2 in WAT displayed
elevated thermogenesis and induction of BAT differentia-
tion within intra-abdominal WAT pads (101). Collectively,
these studies strongly suggest that the sympathetic action in
cold-induced thermogenesis is in part mediated by COX-2.
Furthermore, COX-2 levels may play an important role in
energy balance and body weight homeostasis.
Obesity-activated pro-inﬂammatory signal
transducers, their role in thermogenesis and
diet-induced obesity
Metabolic inﬂammation, a possible mechanism for
obesity-induced leptin resistance
Obesity is characterized by hyperleptinaemia. While this
suggests that excess adiposity may cause leptin resistance
(102), the elevated leptin levels may also be part of a
homeostatic reaction to the excessive caloric intake. In
either case, insufﬁcient leptin signalling may promote posi-
tive energy balance and diet-induced obesity via increased
food consumption and impaired thermogenic response to
excess caloric intake. Two major negative regulators of
leptin signalling are the protein tyrosine phosphatase 1B
(PTP1B) and the suppressor of cytokine signalling 3
(SOCS3). Remarkably, mutant mice that do not express
functional PTP1B in the brain or heterozygote mice for
SOCS3 loss of function mutation are protected from diet-
induced obesity and insulin resistance (103–107). Further-
more, a study showed that compared with control mice,
double mutant mice, which do not express PTP1B and
SOCS3 in neurons are resistant to diet-induced obesity
largely because of increased thermogenesis (108). Meta-
bolic inﬂammation emerged as a molecular mechanism for
obesity-induced leptin resistance. Indeed, it was reported
that PTP1B expression during obesity correlates with
inﬂammation, and that TNFa increases PTP1B mRNA
levels via activation of the transcription factor NF-kB
(109). Similarly, it was shown that SOCS3 induction during
obesity depends on NF-kB activation in neurons (110).
These studies strongly suggest that the expression of major
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negative regulators of leptin signalling, PTP1B and SOCS3,
is induced by pro-inﬂammatory pathways recruited during
obesity (Fig. 3).
Myeloid differentiation primary response gene 88
Myeloid differentiation primary response gene 88
(MYD88) is an adapter protein that functions as scaffold
recruiting pro-inﬂammatory signal cascades downstream to
IL-1R and TLR receptors. It was reported that mice lacking
neuronal MyD88 are protected from diet-induced obesity
and leptin resistance, and display decreased food intake
and increased thermogenesis compared with control mice
(111). The precise pathway linking neuronal MyD88 sig-
nalling to leptin resistance during obesity remains to be
identiﬁed but it was proposed to be mediated by the protein
kinase IKKb, the pro-inﬂammatory signal transducer
responsible for the activation of NF-kB (Fig. 3).
Inhibitor of nuclear factor kappa-B kinase-b
IKKb is part of the IKK complex, comprising the catalytic
subunits IKKa and IKKb, and the regulatory protein IKKg
(112). IKKb is activated in response to several pro-
inﬂammatory signals and is considered to play a major role
in obesity-induced inﬂammation and insulin resistance
(39). In acute inﬂammation, IKKb acts as a sensor and a
signal ampliﬁer where cytokines and PAMPs such as IL-1,
TNFa and LPS potently induce IKKb activity resulting in
increased NF-kB nuclear translocation and consequent
induction of the expression of several inﬂammatory media-
tors including IL-1 and TNFa (112). It was shown that
genetically modiﬁed mice that do not express IKKb in
neurons are protected from diet-induced obesity and leptin
resistance compared with WT control mice (110). The
resistance to diet-induced obesity in mice lacking neuronal
IKKb could be largely explained by decreased food intake
consequent to improved leptin sensing within the hypotha-
lamus. However, given the key role of leptin in diet-induced
thermogenesis, it is possible that an improved thermogenic
response to excess calories also contributes to the obesity-
resistant phenotype of mice with neuronal IKKb inactiva-
tion. At the molecular level, it was proposed that in the
obese hypothalamus, excess adiposity causes endoplasmic
reticulum stress response activating the IKKb NF-kB sig-
nalling pathway, which induces SOCS3 gene expression
and thus leptin resistance (110,113) (Fig. 3).
The inhibitor of nuclear factor kappa-B kinase-e
The inhibitor of NF kappa-B kinase-e (IKKe) is a protein
kinase whose expression is induced by NF-kB during
inﬂammation and that was implicated in the regulation of
NF-kB activity (112). It was proposed that IKKe plays an
important role in energy balance during diet-induced
obesity. Indeed, one study showed that mice lacking IKKe
were protected in a model of diet-induced obesity because
of increased thermogenesis, which was explained by
increased expression of UCP-1 in WAT (114). The relative
importance of IKKe in the promotion of diet-induced
obesity was questioned by another study, as the impact of
IKKe inactivation on diet-induced obesity may depend on
the speciﬁc experimental condition (115). Still, the latter
study supported the role of IKKe in the control of UCP-1
gene expression in WAT. Overall these studies suggest that
IKKe is a negative regulator of thermogenesis possibly by
Figure 3 A possible inﬂammatory
mechanism contributing to reduced leptin
signalling. Obesity is characterized by
hyperleptinaemia possibly consequent to
leptin resistance. The suppressor of cytokine
signalling (SOCS3) and the protein tyrosine
phosphatase (PTP1B) were proposed to be
important negative regulators of leptin
signalling. During obesity cytokines (e.g.
tumour necrosis factor-a [TNFa], and
interleukin [IL]-1b) and long-chain saturated
fatty acids lead to the activation of the
inhibitor of kappa-B kinase (IKK b) nuclear
factor kappa-B (NF-kB) signalling cascade.
NF-kB was shown to be a positive regulator
of SOCS3 and PTP1B gene expression. Thus,
during obesity, increased IKK b signalling
may promote leptin resistance by sustaining
NF-kB dependent SOCS3 and PTP1B gene
expression in leptin sensitive neurons. JAK,
Janus kinase; TLR4, toll-like receptor 4.
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inhibiting brown adipocyte differentiation within WAT
depots. The speciﬁc mechanism by which IKKe regulates
UCP-1 gene expression within WAT remains to be estab-
lished, but it would be interesting to test whether IKKe
controls COX-2 expression in WAT pads.
c-Jun N-terminal kinases and other
mitogen-activated protein kinases
The c-Jun N-terminal kinases (JNK) is a member of the
MAPK family, whose activity is induced in response to
several pro-inﬂammatory and stress signals (116). JNK
activity is chronically elevated during obesity in multiple
tissues and the JNK1 and JNK2 isozymes emerged as major
molecular links connecting obesity, inﬂammation and
insulin resistance (39–41). Indeed mouse genetic studies
showed that JNK1 and JNK2 play an important role in the
promotion of diet-induced obesity (117,118). The role of
JNK1 in diet-induced obesity is largely leptin independent
as leptin-deﬁcient ob/ob mice lacking a functional JNK1
display a leaner phenotype compared with ob/ob mice
expressing JNK1 (118). Obesity resistance in mice lacking
JNK1 is largely due to increased thermogenesis and
depends on its activity within a non-haematopoietic com-
partment (119). Indeed, studies of mouse tissue-conditional
JNK1 gene deletion showed that the brain is a main site for
the obesogenic action of JNK1, and suggested that neuro-
nal JNK1 negatively regulates hypothalamic-mediated
induction of thyroid hormone release (120). Altogether,
these studies support the hypothesis that neuronal JNK1
activity may promote positive energy balance and obesity
by a mechanism involving negative regulation of thyroid
hormone secretion.
JNK1 is not the only MAPK that has been implicated in
diet-induced obesity. Indeed, it was reported that mice that
do not express the extracellular-regulated kinase-1 (ERK1)
are also resistant to diet-induced obesity and display exag-
gerated thermogenic response to food compared with
control mice (121). As the loss of ERK1 did not reduce
obesity in ob/ob mice, the mechanism of action of ERK1 in
diet-induced obesity depends on leptin signalling (122).
Another study implicated the MAPK p38d in obesity-
induced glucose intolerance (123). Interestingly, mice that
do not express p38d are partially protected from diet-
induced obesity (123), although it remains to be established
whether the role of p38d in diet-induced obesity is to
control thermogenesis.
The double-stranded RNA-dependent
protein kinase
The double-stranded RNA-dependent protein kinase (PKR)
was proposed to play a major role in lipid-induced inﬂam-
mation, JNK activation and insulin resistance (124). Mice
bearing a targeted deletion at the PKR gene are protected
from lipid-induced insulin resistance and HFD-induced
glucose and insulin intolerance. Interestingly, mice that
do not express PKR are dramatically protected from
diet-induced obesity compared with WT control mice
(124). PKR activity may promote food intake and decrease
rate of oxygen consumption by a mechanism involving
JNK activation (124). However, the precise molecular
mechanism by which PKR controls energy balance during
diet-induced obesity is still to be identiﬁed.
The class IB phosphatidylinositide-3 kinase
posphatidylinositide-3 kinase (PI3K-g)
The phosphatidylinositide-3 kinase-g PI3Kg is the only
member of class IB phosphatidylinositide-3 kinase that,
unlike the class IA PI3Ks, is not activated by receptor
tyrosine kinases such as the insulin receptor, but is instead
activated by several G-protein coupled receptors (125–
128). PI3Kg signalling is recruited by receptors implicated
in inﬂammation such as chemokine receptors and recep-
tors involved in the control of energy balance and thermo-
genesis such as the angiotensin II AT1 receptors and
b-adrenergic receptors (128–131). Because of its impor-
tance in chemokine signalling, PI3Kg plays a key role in
inﬂammation by promoting leukocyte migration to the
site of infection (128). Interestingly, PI3Kg was also shown
to be a negative regulator of b-adrenergic signalling in
the cardiomyocytes (132,133). The latter may be relevant
to thermogenesis, as cold-induced and diet-induced ther-
mogenesis depend on b-adrenergic signalling (4,6) and
both cold exposure and cafeteria diet increase norepine-
phrine turnover in the heart (9). It was recently proposed
that PI3Kg plays an important role in the link between
obesity, inﬂammation and glucose intolerance (55,134).
Most notably, mice bearing a targeted gene deletion at
the PI3Kg locus are protected from diet-induced obesity
because of decreased feed efﬁciency consequent to
enhanced diet-induced thermogenesis (55). The precise
molecular mechanism linking PI3Kg to diet-induced ther-
mogenesis remains to be identiﬁed; however, it may involve
control of sympathetic signalling in the heart and lipolysis
in WAT (55,132,133). Furthermore, the effects of PI3Kg
inactivation on energy balance depends on leptin signalling
as mice that do not express PI3Kg are protected from
obesity in dietary models, but not in the leptin-deﬁcient
ob/ob model (55,134). Consistent with the data mentioned
earlier, it was recently reported that mice overexpressing
the phosphatase PTEN (phosphatase and tensin homolog),
which counteracts the activity of class I PI3Ks, display
decreased adiposity because of increased thermogenesis
(135). Overall, these results suggest that the class IB PI3Kg
promote positive energy balance and diet-induced obesity
via negative regulation of thermogenesis.
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Final considerations
Environmental temperature, diet (quality and quantity) and
systemic inﬂammation are the three main factors modulat-
ing thermogenesis (2,3). It is now established that obesity is
characterized by a low-grade systemic chronic inﬂamma-
tion, which was proposed by several authors to trigger
pathways promoting positive energy balance (39,41,136,
137). Here are reviewed the pathways that may be impli-
cated in linking obesity-associated metabolic inﬂammation
with thermogenesis and feed efﬁciency. Overall, a large
body of evidence suggests that the cytokines and signalling
molecules described in this review should be regarded as
pleiotropic signal transducers which, on top of their func-
tion in innate immunity, also play an important role in
body weight homeostasis (Figs 2 and 3, and Table 1).
During systemic inﬂammation, complex signalling cascades
are recruited, and each speciﬁc model of systemic inﬂam-
mation is characterized by a speciﬁc signalling network.
Obesity-induced inﬂammation is a peculiar inﬂammatory
state characterized by chronic low-grade increased levels of
several pro-inﬂammatory cytokines and a signiﬁcant eleva-
tion of the levels of the anti-inﬂammatory IL-1Ra. Most
inﬂammatory pathways recruited during obesity were pro-
posed to promote positive energy balance and thus their
inhibition may be beneﬁcial for the treatment of obesity.
However, some of the cytokines recruited during metabolic
inﬂammation (e.g. IL-1, IL-18 and IL-6) as well as COX-2,
may promote thermogenesis and negative energy balance,
and thus could be protective towards the development of
obesity (68,71–77,100,101). It is concluded that a speciﬁc
modulation of metabolic inﬂammation, rather than its sup-
pression, could be a promising strategy for the prevention
and treatment of obesity and related diseases. In support of
this concept are studies showing that pharmacological
administration of the pyrogen CNTF to rodents and
humans leads to reduced body weight compared with con-
trols (86–89,138). CNTF can be seen as a paradigm of the
pleiotropic nature of many cytokines; indeed it acts as a
neuron-survival factor (84), an endogenous pyrogen (85),
as well as an anorexigenic and thermogenic signal impli-
cated in body weight homeostasis (88). There could be
potential limitations and pitfalls in exploiting inﬂammatory
pathways to treat obesity. The development of adverse
effects may be a possible concern, and it is not clear to
which extent it can be possible to achieve stable weight loss
over a long period of time by such approaches. Thus, a
better understanding of the role of metabolic inﬂammation
in the control of body weight homeostasis is necessary. Of
interest, some evidence suggests that metabolic inﬂamma-
Table 1 Possible roles of pro-inﬂammatory signal transducers recruited during obesity in energy balance and thermogenesis
Signal
transducer
Phenotype of mutant mouse in energy balance Molecular mechanism or mechanistic insights References
MyD88 Mice lacking MyD88 in neurons display increased leptin
sensitivity.
Neuronal MyD88 may be implicated in the development
of leptin resistance.
(111)
IKKb Mice lacking IKKb in neurons are resistant to
diet-induced obesity and display increased sensitivity to
leptin.
IKKb activity in neurons may be implicated in leptin
resistance by sustaining NF-kB dependent SOCS3 and
PTP1B gene expression.
(110)
IKKe Mice lacking IKKe display increased UCP-1 levels in
WAT and decreased weight gain in speciﬁc models.
IKKe could be implicated in the control of brown
adipocyte recruitment and activation within speciﬁc WAT
pads.
(114,115)
JNK1 Mice lacking JNK1 display an important
obesity-resistant phenotype largely due to increased
thermogenesis.
JNK1 activity in neurons was proposed to be a negative
regulator of the hypothalamic-thyroid hormone axis.
(117–120)
ERK1 Mice lacking ERK1 are resistant to diet-induced obesity
and display increased thermogenic response to feeding.
ERK1 may promote feeding efficiency via negative
regulation of the thermogenic response to feeding.
(121,122)
p38d Mice lacking p38d display a partial protection from
diet-induced obesity.
The mechanism of the leaner phenotype of mice lacking
p38d is unknown.
(123)
PKR Mice lacking PKR are largely resistant to diet-induced
obesity.
The precise mechanism of action of PKR in diet-induced
obesity is to be established. However, PKR action could
be explained by JNK activation.
(124)
PI3Kg Mice lacking PI3Kg are largely resistant to diet-induced
obesity, display reduced feeding efficiency and
increased diet-induced thermogenesis.
PI3Kg is a negative regulator of diet-induced
thermogenesis. The precise molecular mechanism is not
known, but may involve decreased PKA signalling in
WAT and in cardiomyocytes.
(55,134)
ERK, extracellular-regulated kinase-1; IKK, inhibitor of kappa-B kinase; JNK, c-Jun N-terminal kinases; PKR, protein kinase; PTP1B, protein tyrosine
phosphatase 1B; UCP-1, uncoupling protein; WAT, white adipose tissue.
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tion and thermogenesis could be modulated by nutrients
(139,140). In particular long-chain saturated fatty acids are
considered to be a major cause of metabolic inﬂammation
whereas some unsaturated fatty acids have been shown to
be protective (141–145). Thus, for the future, in addition
to a pharmacological approach, it will be important to
investigate whether speciﬁc pathways linking metabolic
inﬂammation and thermogenesis could be targeted by a
nutraceutical strategy aimed at the prevention of obesity in
overweight individuals as well as obesity relapse after
therapeutic dieting.
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